Business Context and Reporting Period
This Form 8-K filing by Genprex, Inc. (GNPX) was submitted on September 13, 2019, reporting an event that occurred on September 10, 2019. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a regulatory compliance issue regarding the Company's stock price.
Material Changes
The material event reported is a notification from the Nasdaq Listing Qualifications Department. The Company's common stock closing bid price remained below the minimum $1.00 per share requirement for 30 consecutive business days, triggering a deficiency under Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-day period (until March 9, 2020) to regain compliance.
- Remediation Path: Compliance can be achieved if the closing bid price reaches at least $1.00 for 10 consecutive business days during the initial period.
- Future Options: If compliance is not met by the deadline, the Company may be eligible for an additional 180-day period, provided it meets all other listing requirements and notifies Nasdaq of its intent to cure the deficiency.
- Risks: There is no assurance the Company will regain compliance. Failure to do so could result in delisting, though the Company retains the right to appeal such a determination to a Nasdaq Hearings Panel.
- Management Action: Management stated it will monitor the stock price and consider options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of GNPX to assess proximity to the $1.00 threshold.
- Monitor the Company's stock performance over the next 10 consecutive business days to determine if immediate compliance is achieved.
- Review subsequent filings for any announcements regarding reverse stock splits or other corporate actions intended to address the price deficiency.
- Check for any updates on the Company's ability to meet other Nasdaq continued listing requirements if an additional compliance period is sought.